Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | L3MBTL3 | Q96JM7 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2088390 | 0.90 | L3MBTL3 (0.50) | ALDH1A1HPGDKDM4EKMT2AL3MBTL1 | |
| SCHEMBL3092663 | 0.88 | HRH3 (0.39) | ALDH1A1KDM4EKMT2APKMHRH3 | |
| SCHEMBL2086482 | 0.79 | ALDH1A1 (0.62) | ALDH1A1HPGDKDM4ETSHRKMT2A | |
| SCHEMBL2084827 | 0.78 | PKM (0.49) | ALDH1A1HPGDKDM4EKMT2APKM | |
| SCHEMBL3285188 | 0.74 | CCR5 (0.41) | ALDH1A1HPGDKMT2AL3MBTL1SMN1; SMN2 | |
| SCHEMBL3284870 | 0.74 | CCR5 (0.41) | ALDH1A1HPGDKMT2AL3MBTL1SMN1; SMN2 | |
| SCHEMBL5250813 | 0.74 | CCR3 (0.38) | ALDH1A1KDM4EL3MBTL1HRH3SMN1; SMN2 | |
| SCHEMBL6222355 | 0.74 | L3MBTL3 (0.43) | ALDH1A1HPGDKMT2AL3MBTL1SMN1; SMN2 | |
| SCHEMBL3357947 | 0.74 | L3MBTL3 (0.38) | L3MBTL1SMN1; SMN2L3MBTL3GAA | |
| SCHEMBL3279492 | 0.73 | L3MBTL3 (0.50) | ALDH1A1KDM4EKMT2AL3MBTL1L3MBTL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7897603-B2 | Selected CGRP-antagonists, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-03-01 | — | — | US | disclosed |
| US-20090253680-A1 | SELECTED CGRP-ANTAGONISTS, PROCESSES FOR PREPARING THEM AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253680-A1 | SELECTED CGRP-ANTAGONISTS, PROCESSES FOR PREPARING THEM AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | CALCRL, CALCR, BDKRB2 | ALDH1A1 1720/4885HPGD 375/4885KDM4E 4557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.